Home > Press > Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research CongressAbstract:rrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data on the development of ARO-DUX4, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with facioscapulohumeral muscular dystrophy (FSHD), at the...
Producing low-cost hydrogen fuel with the help of magnets
Jul 05, 2021 (Nanowerk News) Hydrogen gas is an environment-friendly fuel, as it produces water upon combustion in the presence of oxygen. For the same weight, hydrogen can provide nearly three times higher energy than gasoline. However, the quantity of hydrogen available from the Earth’s atmosphere is tiny. The more...